Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab

The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, and IIIA nonsmall cell lung cancer (NSCLC). Twenty-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Anticancer Drugs
Autors principals: Marushima, Hideki, Kimura, Hiroyuki, Miyazawa, Tomoyuki, Sakai, Hiroki, Furuya, Naoki, Koji, Kojima, Nakamura, Haruhiko, Saji, Hisashi
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
Clinical Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964868/
https://ncbi.nlm.nih.gov/pubmed/31725045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000857
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars